Sage Journals: Discover world-class research

Abstract

The use of heparin has remained steady for the last 20 years. Significant advances have been made in the understanding of the pathogenesis of clotting disorders and their prevention. Despite these gains, our understanding of the most safe and effective approach to optimizing the dosing of heparin has lagged. With new insight into improvements in outcome related to rapid achievement of the therapeutic range, it has become apparent that the standard approach to heparin dosing is out of date. Individualized heparin dosing based on weight and computer-assisted dosing methods is superior for bringing patients into the desired therapeutic range more quickly, with less cost and better short- and long-term outcomes. Copyright © 1995 by W.B. Saunders Company

Get full access to this article

View all access options for this article.

References

Raschke RA , Reilly BM , Guidry JR, et al : The weight-based heparin dosing nomogram compared with a "Standard Care" nomogram. A randomized controlled trial. Ann Intern Med 119:874-881, 1993

Theroux P. , Ouimet H. , Mc Cans J., et al : Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 319:1105-1111,1988

Hull R. , Raskob G. , Hirsh J., et al : Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 315:1109-1114, 1986

Goldhaber SZ , Morpurgo M. : Diagnosis, treatment, and prevention of pulmonary embolism. Report of the WHO/International Society and Federation of Cardiology Task Force. JAMA 268:1727-1733, 1992

Basu D. , Gallus A. , Hirsh J. , Cade J. : A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 287:324-329, 1972

Hirsh J. : Heparin. N Engl J Med 324:1565-1574, 1991

Mungall DR , Anbe D. , Forrester PL, et al : A prospective randomized comparison of the accuracy of computer-assisted versus GUSTO nomogram-directed heparin therapy. Clin Pharmacol Ther 55:591-596, 1994

Hull RD , Raskob GE , Rosenbloom D., et al : Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 152:1589-1595, 1992

Suchman AL , Griner PF : Diagnostic uses of the activated partial thromboplastin time and prothrombin time. Ann Intern Med 104:810-816, 1986

10.

Cruickshank MK , Levine MN , Hirsh J., et al : A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 151:333-337, 1991

11.

Kandrotas RJ , Gal P. , Douglas JB , Groce JB : Rapid determination of maintenance heparin infusion rates with the use of non-steady-state heparin concentrations. Ann Pharmacother 27:1429-1432, 1993

12.

Hirsh J. , van Aken WG , Gallus A., et al : Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 53:691-694, 1976

13.

Reilly BM , Raschke R. , Srinivas S. , Nieman T. : Intravenous heparin dosing: Patterns and variations in internists' practices . J Gen Intern Med 8:536-542, 1993

14.

Anderson EF : Heparin resistance prior to cardiopulmonary bypass. Anesthesiology 64:504-507, 1986

15.

Cipolle RJ , Uden DL , Gruber SA, et al : Evaluation of a rapid monitoring system to study heparin pharmacokinetics and pharmacodynamics. Pharmacotherapy 10:367-372, 1990

16.

Hirsh J. Heparin therapy in venous thromboembolism. Ann NY Acad Sci 556:378-385, 1989

17.

Research Committee of the British Thoracic Society : Optimum duration of anticoagulation for deep vein thrombosis and pulmonary embolism. Lancet 340:873-876, 1992

18.

White TM , Bernene JL , Mariano AM : Continuous heparin infusion requirements: Diagnostic and therapeutic implications . JAMA 241:2717-2720, 1979

19.

Rooke TW , Osmundson PJ : Heparin and the in-hospital management of deep venous thrombosis: Cost considerations . Mayo Clin Proc 61:198-204, 1986

20.

Cipolle RJ , Seifert RD , Neilan BA, et al : Heparin kinetics: Variables related to disposition and dosage. Clin Pharmacol Ther 29:387-393, 1981

21.

Simon TL , Hyers TM , Gaston JP , Harker LA : Heparin pharmacokinetics: Increased requirements in pulmonary embolism . Br J Haemotol 39:111-120, 1978

22.

Hirsh J. , Dalen JE , Deykin D. , Poller L. : Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 102:337S-351S, 1992

23.

Glazier RL , Crowell EB : Randomized prospective trial of continuous versus intermittent heparin therapy . JAMA 236:1365-1367, 1976

24.

Heit JA : An analysis of current pulmonary embolism therapy. Int Angiol 11:57-63, 1992

25.

Hirsh J. , Cade JF , Regoeczi E., et al : Resolution of experimental pulmonary emboli with heparin and streptokinase in different dosage regimens. J Clin Invest 54:782-791, 1974

26.

Hyers TM , Hull RD , Weg JG : Antithrombotic therapy for venous thromboembolic disease. Chest 95:37S-51S, 1989 (suppl)

27.

Hyers TM , Hull RD , Weg JG : Antithrombotic therapy for venous thromboembolic disease. Chest 102:408S-425S, 1992 (suppl)

28.

Hull RD , Raskob GE , Hirsh J., et al : A randomized double blind trial of intravenous heparin therapy for venous thrombosis: The therapeutic range. Clin Res 31:856-858, 1986

29.

Tenero DM , Bell HE , Deitz DA , Bertino JS : Comparative dosage and toxicity of heparin sodium in the treatment of patients with pulmonary embolism versus deep-vein thrombosis. Clin Pharm 8:40-43, 1989

30.

Girard P. , Mathieu M. , Simonneau G., et al : Recurrence of pulmonary embolism during anticoagulant treatment : A prospective study. Thorax 42:4481-4486, 1987

31.

Saya FG , Coleman LT , Martinoff JT : Pharmacist directed heparin therapy using a standard dosing and monitoring protocol. Am J Hosp Pharm 42:1965-1969, 1985

32.

Pawloski SJ , Kersh PL : Therapeutic heparin monitoring service in a small community hospital . Hosp Pharm 27:703-706, 723, 1992

33.

Rivey MP , Peterson JP : Pharmacy-managed, weight-based heparin protocol. Am J Hosp Pharm 50:279-284, 1993

34.

Chenella FC , Gill MA , Kern JW, et al : Improved method for estimating initial heparin infusion rates. Am J Hosp Pharm 36:782-784, 1979

35.

Nadler SB , Hidalgo JU , Bloch T. : Prediction of blood volume in normal human adults. Surgery 51:224-232, 1962

36.

Chiou WL , Gadalla MA , Peng GW : Method for rapid estimation of total body clearance and adjustment of dosage regimens in patients during constant rate intravenous infusion . J Pharmacokinet Biopharm 6:139-151, 1978

37.

Allen TH , Peng MT , Chen KP, et al : Prediction of blood volume and adiposity in man from body weight and cube of height. Metabolism 5:328-345, 1956

38.

Cipolle RJ , Rodvold KA : Heparin, in Evans WE , Schentag JJ , Jusko WJ (eds): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring . Spokane, WA, Applied Therapeutics, Inc., 1986, pp 908-943

39.

Talstad I. : Heparin therapy adjusted for body weight. Am J Clin Pathol 83:378-381, 1985

40.

Ellison MJ , Sawyer WT , Mills TC : Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 8:65-68, 1989

41.

The GUSTO Investigators : An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673-682, 1993

42.

Hauser VM , Rozek SL : Effect of warfarin on the activated partial thromboplastin time. Drug Intell Clin Pharm 20:964-967, 1986

43.

Mungall D. , Floyd R. : Bayesian forecasting of aPTT response to continuously infused heparin with and without warfarin administration. J Clin Pharmacol 29:1043-1047, 1989

A Review of Common Approaches to Heparin Dosing

Abstract

Get full access to this article

References